Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Entrada Therapeutics in a note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.12) per share for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.42) EPS.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million.
Entrada Therapeutics Price Performance
Shares of TRDA traded down $0.12 during mid-day trading on Wednesday, hitting $7.50. The stock had a trading volume of 103,059 shares, compared to its average volume of 130,987. Entrada Therapeutics has a 52 week low of $7.10 and a 52 week high of $21.79. The business has a fifty day moving average price of $8.64 and a 200-day moving average price of $13.03. The firm has a market cap of $284.65 million, a P/E ratio of 4.72 and a beta of 0.04.
Hedge Funds Weigh In On Entrada Therapeutics
Several large investors have recently modified their holdings of TRDA. KLP Kapitalforvaltning AS bought a new position in shares of Entrada Therapeutics in the fourth quarter worth $36,000. BNP Paribas Financial Markets purchased a new stake in Entrada Therapeutics during the fourth quarter valued at about $57,000. Virtus ETF Advisers LLC purchased a new stake in Entrada Therapeutics in the fourth quarter worth approximately $68,000. AlphaQuest LLC bought a new position in shares of Entrada Therapeutics during the 4th quarter valued at $70,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Entrada Therapeutics by 53,455.6% in the fourth quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after buying an additional 4,811 shares during the period. Hedge funds and other institutional investors own 86.39% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Stories
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
